| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
Nasopharyngeal carriage rate of Streptococcus pneumoniae in Japanese infants didn't change before and after the introduction of 13th-valent pneumococcal conjugate vaccine (PCV13).Among carriage pneumococcus strains, all strains changed non PCV13 serotypes and nontypeable S.pneumoniae strains increased after the introduction of PCV13. Clonally related serotype 12F,that is one of non PCV13 serotypes,increased the pathogen of invasive pneumococcal diseases (IPD) in Japan.
The titers of PCV13 serotype specific antibodies in non PCV13 immunized Japanese children with underlying disease was relatively lower than healthy Japanese children. This study result suggests that the recommendation of PCV13 is needed for non PCV13 immunized Japanese children with underlying diseases.The titers of non PCV13 serotype specific antibody in PCV13 immunized children with IPD were varied. The effects of PCV13 immunization against immune response of non PCV13 specific serotype pneumococcus was not clarified.
|
